Part two focuses on the requirement that Part D sponsors must make enrollees aware of upcoming benefits.
medicare © Felix Pergande - stock.adobe.com
The U.S. Department of Health and Human Services released the final part two guidance for the Medicare Prescription Drug Payment Plan on July 16, according to a news release on their website.
Starting in January 2025, Medicare beneficiaries will be able to spread their prescription drug costs across the calendar year rather than pay the full cost every time they go to the pharmacy.
Part one guidance was released in February of this year and focused on operational requirements for the program.
Part two of this plan was released to ensure that people with Medicare Part D drug coverage are aware of the payment options. In the new program, Medicare beneficiaries will pay nothing for covered Part D drugs. Instead, Part D sponsors will bill the beneficiaries monthly until the payment is made in full. Sponsors will then pay the pharmacies.
This program will launch at the same time as Medicare beneficiaries are having their out-of-pocket annual medication costs capped at $2,000.
Part D plan sponsors will be required to reach out to enrollees who spent at least $2,000 on drugs from January 1 and September 30 of this year.
The CMS will provide resources online that include a cost preview in the Medicare Finder. There will also be training sessions held for Medicare partners.
The CMS will also be publishing six model documents to help Part D sponsors meet their education and outreach requirements.
These changes are all part of the Inflation Reduction Act, established in 2022.
Some ways the Inflation Reduction Act has helped reduce costs so far include:
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More